Use of <sup>64</sup>Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study.
Where this comes from
- Record sourced from PubMed, PMID 34857660.
- Also identified by DOI 10.2967/jnumed.121.262940 and PMC identifier 9364339.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We hypothesized that functional imaging with <sup>64</sup>Cu-DOTA-trastuzumab PET/CT would predict the response to the antibody-drug conjugate trastuzumab-emtansine (T-DM1). <b>Methods:</b> Ten women with metastatic human epidermal growth factor receptor 2-positive breast cancer underwent <sup>18</sup>F-FDG PET/CT and <sup>64</sup>Cu-DOTA-trastuzumab PET/CT on days 1 and 2 before treatment with T-DM1. <b>Results:</b> T-DM1-responsive patients had higher uptake than nonresponsive patients. Day 1 minimum SUV<sub>max</sub> (5.6 vs. 2.8, <i>P</i> < 0.02), day 2 minimum SUV<sub>max</sub> (8.1 vs. 3.2, <i>P</i> < 0.01), and day 2 average SUV<sub>max</sub> (8.5 vs. 5.4, <i>P</i> < 0.05) for <sup>64</sup>Cu-DOTA-trastuzumab all favored responding patients. Tumor-level response suggested threshold dependence on SUV<sub>max</sub> Patients with a day 2 minimum SUV<sub>max</sub> above versus below the threshold had a median time to treatment failure of 28 mo versus 2 mo (<i>P</i> < 0.02). <b>Conclusion:</b> Measurement of trastuzumab uptake in tumors via PET/CT is promising for identifying patients with metastatic breast cancer who will benefit from T-DM1.
Medical subject headings
- Breast Neoplasms